Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Revenue (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Revenue for 16 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • For Q4 2025, Revenue rose 118.89% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $39.6 million, down 30.3%, while the annual FY2025 figure was $39.6 million, 31.57% down from the prior year.
  • Revenue hit $14.2 million in Q4 2025 for Sangamo Therapeutics, up from $581000.0 in the prior quarter.
  • Across five years, Revenue topped out at $158.0 million in Q1 2023 and bottomed at $356000.0 in Q2 2024.
  • Average Revenue over 5 years is $24.6 million, with a median of $18.3 million recorded in 2025.
  • Year-over-year, Revenue tumbled 99.7% in 2024 and then skyrocketed 5042.13% in 2025.
  • Sangamo Therapeutics' Revenue stood at $28.6 million in 2021, then fell by 4.67% to $27.2 million in 2022, then crashed by 92.5% to $2.0 million in 2023, then soared by 218.32% to $6.5 million in 2024, then skyrocketed by 118.89% to $14.2 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $14.2 million, $581000.0, and $18.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.